{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-021495","form_type":"8-K","ticker":"ITRMF","cik":"0001659323","company_name":"Iterum Therapeutics plc","filed_at":"2023-05-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.881237+00:00","generated_at":"2026-06-15T02:36:53.147148+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Iterum Therapeutics Q1 net loss $9.9M; cash $51.8M; REASSURE trial on track","bullets":["Net loss Q1 2023 $9.9M vs $3.5M Q1 2022; non-GAAP net loss $7.4M vs $5.6M.","Cash and investments $51.8M as of March 31, 2023; expected to fund operations until mid-2024.","R&D expense $6.4M (up from $3.4M) due to REASSURE; G&A $2.1M (down from $3.9M).","REASSURE trial enrollment ongoing; completion expected H1 2024; interim analysis H2 2023.","Approximately 12.9M ordinary shares outstanding as of April 30, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-021495","json":"https://secwatch.observer/filing/0000950170-23-021495.json","markdown":"https://secwatch.observer/filing/0000950170-23-021495.md","text":"https://secwatch.observer/filing/0000950170-23-021495.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1659323/000095017023021495/0000950170-23-021495-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1659323/000095017023021495/itrm-20230512.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T02:36:53.147148+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"331612aedc63f52e7f432767155792d0103ce69f","claim":"Iterum Therapeutics plc reported first quarter ended March 31, 2023 results: net income Net loss for the first quarter 2023 was $9.9 million.","evidence_excerpt":"Iterum Therapeutics plc issued a press release announcing its financial results for the first quarter ended March 31, 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1659323/000095017023021495/0000950170-23-021495-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2023"},{"label":"Net income","value":"Net loss for the first quarter 2023 was $9.9 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"331612aedc63f52e7f432767155792d0103ce69f","claim":"Iterum Therapeutics plc reported first quarter ended March 31, 2023 results: net income Net loss for the first quarter 2023 was $9.9 million.","evidence_excerpt":"Net loss for the first quarter 2023 was $9.9 million, compared to a net loss of $3.5 million for the same period in 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1659323/000095017023021495/0000950170-23-021495-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2023"},{"label":"Net income","value":"Net loss for the first quarter 2023 was $9.9 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}